1   Supplementary Table 1. Laboratory and clinical features of patients according to presence (MACE+) or absence (MACE-) of major adverse cardiovascular events.

Laboratory and angiographic data	Whole population (n=333)			L34-carriers (n=126, 37.8%)			VV34 homozygotes (n=207, 62.2%)		
	MACE +	MACE -	P	MACE +	MACE -	P	MACE +	MACE -	P
Creatinine basal value (mg/dl, mean ±SD)	1.46 ±1.4	0.96 ±0.4	<0.0001	1.4 ±0.9	0.9 ±0.2	0.0001	1.5 ±1.7	1.0 ±0.4	0.0011
Creatinine peak value (mg/dl, mean ±SD)	1.84 ±1.7	1.1 ±1.0	<0.0001	1.9 ±1.6	1.0 ±0.3	<0.0001	1.8 ±1.9	1.1 ±0.8	0.0018
Total Cholesterol (mg/dl, mean ±SD)	169.0 ±41.4	195.6 ±42.6	<0.0001	171.5 ±43.6	185.7 ±42.6	n.s	168.6 ±41.2	201.2 ± 47.8	<0.0001
HDL (mg/dl, mean ±SD)	44.7 ±14.6	46.5 ±12.5	n.s.	45.0 ±12.9	44.9 ±11.3	n.s	44.5 ±15.7	45.9 ±12.0	n.s
LDL (mg/dl, mean ±SD)	99.4 ±34.7	122.8 ±42.3	<0.0001	102.3 ±38.4	115.2 ±38.3	n.s	98.7 ±33.8	127.1 ± 48.0	0.0002
Triglycerides (mg/dl, mean ±SD)	124.5 ±61.6	136.1 ±69.9	n.s.	121.2 ±56.7	127.6 ±59.4	n.s	126.8 ± 64.7	141.3 ± 75.9	n.s
Glycated hemoglobin (%, mean ±SD)	6.6 ±1.4	6.3 ±1.2	0.014	6.6 ±1.2	6.2 ±1.0	n.s	6.7 ±1.5	6.3 ±1.2	n.s
Uric acid (mg/dl, mean ±SD)	6.2 ±1.9	5.91 ±1.74	n.s	6.1 ±1.9	5.6 ±1.7	n.s	6.2 ±1.9	5.9 ±1.6	n.s
CAD extent									
Single-vessel disease	30.4	42.7	0.03	32	47	0.0498	29	40	n.s
Double-vessel disease	31.3	29.4	n.s	27	28	n.s	34	30	n.s
Triple-vessel disease	38.3	28.4	n.s	41	25	n.s	37	30	n.s
N° of stent									
0	20.0	25.8	n.s	11	18	n.s	26	21	n.s
1	42.6	45.0	n.s	47	51	n.s	40	50	n.s
2	23.5	21.5	n.s	26	23	n.s	21	21	n.s
3	6.1	3.6	0.0001	5	5	n.s	7	3	n.s
4 or more	7.8	4.0	n.s	10	3	n.s	6	5	n.s
Type of stent									
BMS	45.2	33.9	0.05	55	36	0.0333	39	33	n.s
DES	36.5	44.9	n.s	37	46	n.s	37	45	n.s
POBA	17.4	20.2	n.s	8	18	n.s	24	22	n.s

2   CAD = coronary artery disease; BMS = bare metal stent; DES = drug eluting stent; POBA = percutaneous only balloon angioplasty; n.s., indicates not significant.